{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:08:45Z","timestamp":1790536125431,"version":"4.1.0"},"reference-count":54,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"crossref","award":["Grant Agreement N\u00b0 945393"],"award-info":[{"award-number":["Grant Agreement N\u00b0 945393"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Italian Ministry of Health and Alliance Against Cancer, Ricerca Corrente CAR-T project","award":["RCR-2019-23669115"],"award-info":[{"award-number":["RCR-2019-23669115"]}]},{"name":"European Union\u2019s Horizon 2020 CARAMBA","award":["Grant Agreement N\u00b0 754658"],"award-info":[{"award-number":["Grant Agreement N\u00b0 754658"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,12,10]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To date, T cells redirected with CD19-specific chimeric antigen receptors (CAR) have gained impressive success in B-cell malignancies. However, treatment failures are common and the occurrence of severe toxicities, such as cytokine release syndrome (CRS), still limits the full exploitation of this approach. Therefore, the development of cell products with improved therapeutic indexes is highly demanded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this project, we investigated how CD4 and CD8 populations cooperate during CD19 CAR-T cell responses and what is their specific role in CRS development. To this aim, we took advantage of immunodeficient mice reconstituted with a human immune system (HuSGM3) and engrafted with the B-cell acute lymphoblastic leukemia cell line NALM-6, a model that allows to thoroughly study efficacy and toxicity profiles of CD19 CAR-T cell products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CD4 CAR-T cells showed superior proliferation and activation potential, which translated into stronger stimulation of myeloid cells, the main triggers of adverse events. Accordingly, toxicity assessment in HuSGM3 mice identified CD4 CAR-T cells as key contributors to CRS development, revealing a safer profile when they harbor CARs embedded with 4-1BB, rather than CD28. By comparing differentially co-stimulated CD4:CD8 1:1 CAR-T cell formulations, we observed that CD4 cells shape the overall expansion kinetics of the infused product and are crucial for maintaining long-term responses. Interestingly, the combination of CD4.BBz with CD8.28z CAR-T cells resulted in the lowest toxicity, without impacting antitumor efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Taken together, these data point out that the rational design of improved adoptive T-cell therapies should consider the biological features of CD4 CAR-T cells, which emerged as crucial for maintaining long-term responses but also endowed by a higher toxic potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-005878","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T10:50:14Z","timestamp":1672656614000},"page":"e005878","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":59,"title":["CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses"],"prefix":"10.1136","volume":"11","author":[{"given":"Camilla","family":"Bove","sequence":"first","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Arcangeli","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Falcone","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Camisa","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Experimental Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"El Khoury","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Greco","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Lucia","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bergamini","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Bondanza","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[{"name":"Experimental Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-9060","authenticated-orcid":false,"given":"Monica","family":"Casucci","sequence":"additional","affiliation":[{"name":"Innovative Immunotherapies Unit, IRCCS Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"2025100314355569000_11.1.e005878.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100314355569000_11.1.e005878.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100314355569000_11.1.e005878.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2025100314355569000_11.1.e005878.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100314355569000_11.1.e005878.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100314355569000_11.1.e005878.6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025100314355569000_11.1.e005878.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"2025100314355569000_11.1.e005878.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.018"},{"key":"2025100314355569000_11.1.e005878.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100314355569000_11.1.e005878.10","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"2025100314355569000_11.1.e005878.11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100314355569000_11.1.e005878.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"2025100314355569000_11.1.e005878.13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025100314355569000_11.1.e005878.14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4241"},{"key":"2025100314355569000_11.1.e005878.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100314355569000_11.1.e005878.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446"},{"key":"2025100314355569000_11.1.e005878.17","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2025100314355569000_11.1.e005878.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2025100314355569000_11.1.e005878.19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100314355569000_11.1.e005878.20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"2025100314355569000_11.1.e005878.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"2025100314355569000_11.1.e005878.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"2025100314355569000_11.1.e005878.23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.247"},{"key":"2025100314355569000_11.1.e005878.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"2025100314355569000_11.1.e005878.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"2025100314355569000_11.1.e005878.26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cpt.2561","article-title":"In vivo cellular expansion of Lisocabtagene Maraleucel and association with efficacy and safety in relapsed\/refractory large B-cell lymphoma","volume":"112","author":"Ogasawara","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025100314355569000_11.1.e005878.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2025100314355569000_11.1.e005878.28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"2025100314355569000_11.1.e005878.29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4939-3338-9_10","article-title":"Exploiting secreted luciferases to monitor tumor progression in vivo","volume":"1393","author":"Falcone","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2025100314355569000_11.1.e005878.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers"},{"key":"2025100314355569000_11.1.e005878.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0"},{"key":"2025100314355569000_11.1.e005878.32","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2020.05.017"},{"key":"2025100314355569000_11.1.e005878.33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-018-0942-x","article-title":"Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population","volume":"20","author":"Schmidt","year":"2018","journal-title":"Breast Cancer Res"},{"key":"2025100314355569000_11.1.e005878.34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"2025100314355569000_11.1.e005878.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6"},{"key":"2025100314355569000_11.1.e005878.36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100314355569000_11.1.e005878.37","doi-asserted-by":"crossref","first-page":"99048","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"2025100314355569000_11.1.e005878.38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1209"},{"key":"2025100314355569000_11.1.e005878.39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100314355569000_11.1.e005878.40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"2025100314355569000_11.1.e005878.41","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol Ther"},{"key":"2025100314355569000_11.1.e005878.42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e318194a921","article-title":"Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells","volume":"32","author":"Cheadle","year":"2009","journal-title":"J Immunother"},{"key":"2025100314355569000_11.1.e005878.43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344"},{"key":"2025100314355569000_11.1.e005878.44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600769"},{"key":"2025100314355569000_11.1.e005878.45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003486"},{"key":"2025100314355569000_11.1.e005878.46","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial Axicabtagene Ciloleucel and Tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"key":"2025100314355569000_11.1.e005878.47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129632","article-title":"Utilization of immune checkpoint inhibitors for relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL) in oncology community practices","volume":"134","author":"Gajra","year":"2019","journal-title":"Blood"},{"key":"2025100314355569000_11.1.e005878.48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"2025100314355569000_11.1.e005878.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"2025100314355569000_11.1.e005878.50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100314355569000_11.1.e005878.51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945"},{"key":"2025100314355569000_11.1.e005878.52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000034"},{"key":"2025100314355569000_11.1.e005878.53","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753"},{"key":"2025100314355569000_11.1.e005878.54","doi-asserted-by":"crossref","first-page":"96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:36:04Z","timestamp":1759527364000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,2]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/jitc-2022-005878"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005878","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}